<DOC>
	<DOCNO>NCT00210977</DOCNO>
	<brief_summary>The purpose study assess presence anti erythropoietin antibody ( anti EPO Ab ) participant respond erythropoietin receptor agonist ( ERA ) therapy treat prevent anemia without loss effectiveness see develop pure red cell aplasia loss effectiveness recombinant erythropoietin measure duration effectiveness ERA therapy .</brief_summary>
	<brief_title>A Study Patients Treated With Erythropoietin Receptor Agonists Anemia Who Developed Anti-erythropoietin Antibodies</brief_title>
	<detailed_description>This observational ( study investigators/physicians observe participant 's data measure outcomes ) , international , multicenter ( study conduct multiple site ) , cohort ( group individual similar characteristic ) study . The study consist prestudy phase , observational phase ( 2 year ) , follow-up phase ( 1 year ) . Approximately 50 participant already receive ERA therapy anemia observe study . In observational phase , participant ' erythropoietin antibody status ( positive negative ) , clinical progress , treatment anemia prevention anemia , outcome monitor . During study , enrol participant continue receive standard-of-care treatment disease individual investigator enrollment study . Safety evaluation include assessment adverse event monitor throughout study . The total duration study 3 year .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Receiving ERA therapy cause anemia respond ERA therapy least 3 month Positive borderline serum antibody erythropoietin identify serum radioimmunoprecipitation Maintained stable hemoglobin within 3month period decrease 2 g/dL 1month period increase red blood cell transfusion requirement An ERA maintenance dose increase 50 percentage initial effective dose If blood count information available , must count reticulocyte ( immature red blood cell ) great equal 30 million/L Stem cell bone marrow transplantation Treatment medication decrease ability immune system function normally , within last 3 month Participants show loss effectiveness ERA therapy , define participant initially respond treatment anemia [ rise hemoglobin last minimum 3 month ] follow unexplained decrease hemoglobin ( great equal 2 g/dL ) within 1month period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>Erythropoietin receptor agonist ( ERA ) therapy</keyword>
	<keyword>Anti-erythropoietin antibody ( anti-EPO Ab )</keyword>
	<keyword>Recombinant human erythropoietin</keyword>
	<keyword>Pure red cell aplasia</keyword>
	<keyword>Darbepoetin</keyword>
</DOC>